X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Merck Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs MERCK LTD - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA MERCK LTD SANOFI INDIA/
MERCK LTD
 
P/E (TTM) x 38.2 44.0 86.9% View Chart
P/BV x 7.2 6.4 112.4% View Chart
Dividend Yield % 0.5 0.5 99.5%  

Financials

 SANOFI INDIA   MERCK LTD
EQUITY SHARE DATA
    SANOFI INDIA
Dec-17
MERCK LTD
Dec-17
SANOFI INDIA/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs4,9451,358 364.3%   
Low Rs3,901933 418.1%   
Sales per share (Unadj.) Rs1,081.8665.0 162.7%  
Earnings per share (Unadj.) Rs141.656.6 250.2%  
Cash flow per share (Unadj.) Rs185.972.5 256.5%  
Dividends per share (Unadj.) Rs33.0015.00 220.0%  
Dividend yield (eoy) %0.71.3 57.0%  
Book value per share (Unadj.) Rs868.8441.7 196.7%  
Shares outstanding (eoy) m23.0316.60 138.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.11.7 237.4%   
Avg P/E ratio x31.220.2 154.3%  
P/CF ratio (eoy) x23.815.8 150.5%  
Price / Book Value ratio x5.12.6 196.4%  
Dividend payout %23.326.5 87.9%   
Avg Mkt Cap Rs m101,86219,011 535.8%   
No. of employees `0003.21.5 209.8%   
Total wages/salary Rs m3,6851,696 217.2%   
Avg. sales/employee Rs Th7,691.97,150.0 107.6%   
Avg. wages/employee Rs Th1,137.71,098.7 103.5%   
Avg. net profit/employee Rs Th1,006.5608.2 165.5%   
INCOME DATA
Net Sales Rs m24,91411,040 225.7%  
Other income Rs m807240 336.7%   
Total revenues Rs m25,72111,279 228.0%   
Gross profit Rs m5,3721,376 390.4%  
Depreciation Rs m1,022264 387.1%   
Interest Rs m110-   
Profit before tax Rs m5,1461,352 380.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0170 0.0%   
Tax Rs m1,886583 323.6%   
Profit after tax Rs m3,260939 347.1%  
Gross profit margin %21.612.5 173.0%  
Effective tax rate %36.643.1 85.0%   
Net profit margin %13.18.5 153.8%  
BALANCE SHEET DATA
Current assets Rs m14,4327,523 191.8%   
Current liabilities Rs m6,0102,253 266.8%   
Net working cap to sales %33.847.7 70.8%  
Current ratio x2.43.3 71.9%  
Inventory Days Days6152 116.7%  
Debtors Days Days2841 70.2%  
Net fixed assets Rs m7,9911,240 644.6%   
Share capital Rs m230166 138.7%   
"Free" reserves Rs m19,7787,167 276.0%   
Net worth Rs m20,0087,333 272.9%   
Long term debt Rs m00-   
Total assets Rs m27,7709,912 280.2%  
Interest coverage x468.8NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.91.1 80.6%   
Return on assets %11.89.5 124.3%  
Return on equity %16.312.8 127.2%  
Return on capital %25.820.8 124.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m6,3061,015 621.5%   
Fx outflow Rs m5,2573,043 172.8%   
Net fx Rs m1,049-2,028 -51.7%   
CASH FLOW
From Operations Rs m4,351537 810.8%  
From Investments Rs m-787-476 165.2%  
From Financial Activity Rs m-1,884-220 857.1%  
Net Cashflow Rs m1,680-160 -1,053.3%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 60.4 51.8 116.6%  
Indian inst/Mut Fund % 14.4 18.2 79.1%  
FIIs % 14.6 1.0 1,460.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 29.1 36.1%  
Shareholders   15,184 28,591 53.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   NATCO PHARMA  PLETHICO PHARMA  WOCKHARDT LTD.  TORRENT PHARMA  FRESENIUS KABI ONCO.  

Compare SANOFI INDIA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 629 Points Higher; Realty and Auto Stocks Witness Buying(Closing)

Indian share markets continued their momentum throughout the day and ended the day on a strong note. Gains were largely seen in the realty sector, telecom sector and auto sector.

Related Views on News

SANOFI INDIA Announces Quarterly Results (2QFY19); Net Profit Up 2.5% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, SANOFI INDIA has posted a net profit of Rs 1 bn (up 2.5% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

MERCK LTD Announces Quarterly Results (2QFY19); Net Profit Up 29.8% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, MERCK LTD has posted a net profit of Rs 411 m (up 29.8% YoY). Sales on the other hand came in at Rs 2 bn (down 27.7% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Dec 12, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 8-QTR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS